HOUSE BILL 1131

J1, F2 5lr2053

By: Delegates Vogel and Tomlinson

Introduced and read first time: February 5, 2025 Assigned to: Health and Government Operations

Committee Report: Favorable

House action: Adopted

Read second time: March 1, 2025

CHAPTER

- 1 AN ACT concerning
- 2 Public Health Buprenorphine Training Grant Program and Workgroup
- 3 FOR the purpose of establishing the Buprenorphine Training Grant Program to assist
- 4 counties with offsetting the cost of training paramedics to administer buprenorphine;
- 5 including the Program as an authorized use of funding from the Opioid Restitution
- Fund; requiring the Maryland Office of Overdose Response to convene a workgroup
- 7 to study access to buprenorphine in the State; and generally relating to
- 8 buprenorphine.
- 9 BY adding to
- 10 Article Health General
- 11 Section 13–5501 and 13–5502 to be under the new subtitle "Subtitle 55.
- 12 Buprenorphine Training Grant Program"
- 13 Annotated Code of Maryland
- 14 (2023 Replacement Volume and 2024 Supplement)
- 15 BY repealing and reenacting, without amendments,
- 16 Article State Finance and Procurement
- 17 Section 7–331(a) through (e)
- 18 Annotated Code of Maryland
- 19 (2021 Replacement Volume and 2024 Supplement)
- 20 BY repealing and reenacting, with amendments,
- 21 Article State Finance and Procurement
- 22 Section 7–331(f)

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.

<u>Underlining</u> indicates amendments to bill.

Strike out indicates matter stricken from the bill by amendment or deleted from the law by amendment.



- 1 Annotated Code of Maryland
- 2 (2021 Replacement Volume and 2024 Supplement)
- 3 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
- 4 That the Laws of Maryland read as follows:
- 5 Article Health General
- 6 SUBTITLE 55. BUPRENORPHINE TRAINING GRANT PROGRAM.
- 7 **13–5501**.
- 8 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
- 9 INDICATED.
- 10 (B) "PARAMEDIC" HAS THE MEANING STATED IN § 13–516 OF THE
- 11 EDUCATION ARTICLE.
- 12 (C) "PROGRAM" MEANS THE BUPRENORPHINE TRAINING GRANT
- 13 **PROGRAM.**
- 14 **13–5502.**
- 15 (A) (1) THERE IS A BUPRENORPHINE TRAINING GRANT PROGRAM IN
- 16 THE DEPARTMENT.
- 17 (2) THE PURPOSE OF THE PROGRAM IS TO ASSIST A COUNTY WITH
- 18 OFFSETTING THE COST OF TRAINING PARAMEDICS TO ADMINISTER
- 19 BUPRENORPHINE.
- 20 (B) A COUNTY MAY APPLY TO THE DEPARTMENT FOR A GRANT FROM THE
- 21 **PROGRAM.**
- 22 (C) A COUNTY MAY USE A GRANT AWARDED UNDER THE PROGRAM ONLY
- 23 FOR TRAINING PARAMEDICS TO ADMINISTER BUPRENORPHINE.
- 24 (D) THE GOVERNOR SHALL INCLUDE IN THE ANNUAL BUDGET BILL AN
- 25 APPROPRIATION OF AT LEAST \$50,000 FROM THE OPIOID RESTITUTION FUND FOR
- 26 THE PROGRAM.
- 27 Article State Finance and Procurement
- 28 7–331.
- 29 (a) In this section, "Fund" means the Opioid Restitution Fund.

- 1 (b) There is an Opioid Restitution Fund.
- 2 (c) The purpose of the Fund is to retain the amount of settlement revenues 3 deposited to the Fund in accordance with subsection (e)(1) of this section.
- 4 (d) (1) The Fund is a special, nonlapsing fund that is not subject to § 7–302 of this subtitle.
- 6 (2) The State Treasurer shall hold the Fund separately, and the 7 Comptroller shall account for the Fund.
- 8 (e) The Fund consists of:
- 9 (1) all revenues received by the State from any source resulting, directly or 10 indirectly, from any judgment against, or settlement with, opioid manufacturers, opioid 11 research associations, or any other person in the opioid industry relating to any claims 12 made or prosecuted by the State to recover damages for violations of State law; and
- 13 (2) the interest earnings of the Fund.
- 14 (f) The Fund may be used only to provide funds for:
- 15 (1) programs, services, supports, and resources for evidence—based 16 substance use disorder prevention, treatment, recovery, or harm reduction that have the 17 purpose of:
- 18 (i) improving access to medications proven to prevent or reverse an overdose, including by supporting the initiative to co-locate naloxone with automated external defibrillators placed in public buildings under § 13–518 of the Education Article;
- 21 (ii) supporting peer support specialists and screening, brief 22 intervention, and referral to treatment services for hospitals, correctional facilities, and 23 other high–risk populations;
- 24 (iii) increasing access to medications that support recovery from 25 substance use disorders;
- 26 (iv) expanding the Heroin Coordinator Program, including for 27 administrative expenses;
- 28 (v) expanding access to crisis beds and residential treatment 29 services for adults and minors;
- 30 (vi) expanding and establishing safe stations, mobile crisis response 31 systems, and crisis stabilization centers;

31

(b)

- 1 (vii) supporting the behavioral health crisis hotline; 2 (viii) organizing primary and secondary school education campaigns 3 to prevent opioid use, including for administrative expenses; 4 (ix) enforcing the laws regarding opioid prescriptions and sales. 5 including for administrative expenses; 6 (x) research regarding and training for substance use treatment and 7 overdose prevention, including for administrative expenses; and 8 (xi) supporting and expanding other evidence-based interventions 9 for overdose prevention and substance use treatment; 10 (2)supporting community-based nonprofit recovery organizations that 11 provide nonclinical substance use recovery support services in the State; 12 (3)evidence-informed substance use disorder prevention, treatment 13 recovery, or harm reduction pilot programs or demonstration studies that are not evidence-based if the Opioid Restitution Fund Advisory Council, established under § 14 7.5–902 of the Health – General Article: 15 16 determines that emerging evidence supports the distribution of 17 money for the pilot program or that there is a reasonable basis for funding the 18 demonstration study with the expectation of creating an evidence-based program; and 19 (ii) approves the use of money for the pilot program or demonstration study; [and] 20 21evaluations of the effectiveness and outcomes reporting for substance 22use disorder abatement infrastructure, programs, services, supports, and resources for 23which money from the Fund was used, including evaluations of the impact on access to harm reduction services or treatment for substance use disorders and the reduction in 2425 drug-related mortality; AND **BUPRENORPHINE TRAINING** 26 **(5)** THE GRANT **PROGRAM** 27 ESTABLISHED UNDER § 13–5502 OF THE HEALTH – GENERAL ARTICLE. 28 SECTION 2. AND BE IT FURTHER ENACTED, That: 29 (a) The Maryland Office of Overdose Response shall convene a workgroup to study access to buprenorphine in the State. 30
- 32 (1) one member of the Senate of Maryland, appointed by the President of 33 the Senate;

The workgroup shall include:

$\frac{1}{2}$	House; and	(2)	one member of the House of Delegates, appointed by the Speaker of the
3		(3)	representatives of:
4			(i) the Maryland Institute of Emergency Medical Services Systems;
5			(ii) the Behavioral Health Administration;
6			(iii) hospitals;
7			(iv) local behavioral health agencies; and
8			(v) the Maryland Association of Counties.
9	(c)	The v	vorkgroup shall examine:
0		(1)	how buprenorphine services are offered in the State;
1		(2)	the capacity of providers to provide buprenorphine;
$\frac{12}{3}$	may exist;	(3)	any geographic areas where significant gaps in buprenorphine services
14 15	buprenorph	(4) ine ser	the feasibility of financial support for a long-term expansion of vices;
16 17	improvemen	(5) nt of bu	a plan for ongoing data collection for the purpose of the monitoring and aprenorphine services;
18 19	buprenorph	(6) ine in	how to effectively grow a hub–and–spoke model to ensure access to the State; and
20 21	State.	(7)	any other strategies that would improve buprenorphine services in the
22 23 24 25 26	need for any State Gover	t a repo y statu rnmen	r before December 31, 2025, the Maryland Office of Overdose Response ort on the findings and recommendations of the workgroup, including the story changes, to the Governor and, in accordance with § 2–1257 of the t Article, the Senate Finance Committee and the House Health and ations Committee.
27 28 29	effect Octob	er 1, 20	3. AND BE IT FURTHER ENACTED, That Section 1 of this Act shall take 025. Section 1 of this Act shall remain in effect for a period of 5 years and, ember 30, 2030, Section 1 of this Act, with no further action required by

the General Assembly, shall be abrogated and of no further force and effect.

30

 SECTION 4. AND BE IT FURTHER ENACTED, That, except as provided in Section 3 of this Act, this Act shall take effect July 1, 2025. Section 2 of this Act shall remain effective for a period of 1 year and, at the end of June 30, 2026, Section 2 of this Act, with no further action required by the General Assembly, shall be abrogated and of no further force and effect.

approved:	
	Governor.
	Speaker of the House of Delegates.

President of the Senate.